On January 16th, Professor Lu Shun from the Affiliated Chest Hospital of Shanghai Jiao Tong University School of Medicine conducted a Phase III study (NEOTORCH) on the combined use of Treprizumab and chemotherapy for perioperative treatment of resectable non-small cell lung cancer (NSCLC), which was published in the top international authoritative journal, Journal of the American Medical Association (JAMA, influencing factor: 120.7), Becoming the world's first JAMA flagship study on perioperative immunotherapy for lung cancer (covering both neoadjuvant and adjuvant), setting a new benchmark for perioperative treatment of lung cancer. Source: The NEOTORCH Study (NCT04158440) on the official website of JAMA is a randomized, double-blind, placebo-controlled phase III clinical study aimed at comparing the efficacy and safety of Teripilimumab or placebo combined chemotherapy for perioperative treatment of resectable stage II-III NSCLC patients. As the world's first phase III clinical study using anti-PD-1 monoclonal antibodies to achieve event free survival (EFS) positive results in the perioperative period (including neoadjuvant and adjuvant therapy) of NSCLC, NEOTORCH announced the EFS interim analysis results of stage III NSCLC patients at the April 2023 American Society of Clinical Oncology (ASCO) General Assembly Series and ASCO Annual Meeting, which received widespread attention from international scholars. This time, it has been published in the SCI academic journal JAMA, which ranks among the top 4 globally, making Treprizumab the first domestically produced PD - (L) 1 inhibitor to reach the top of JAMA's main journal twice. Professor Lu Shun, the main researcher of NEOTORCH research, stated that, "Whether it is clinical diagnosis and treatment level or clinical research ability, we have gradually transformed from being a 'follower' to a 'follower' and even become a 'leader' in some aspects. More and more innovative solutions from China are rooted in China, going global, and ultimately changing global treatment standards. The publication of NEOTORCH by JAMA is a starting point, and China's original '3+1+13' perioperative treatment model has the highest evidence-based medical value.", We will establish new treatment standards for patients and bring changes to the diagnosis and treatment pattern of lung cancer in China and even the world As the largest prospective phase III clinical study currently included in China for resectable stage III NSCLC patients, NEOTORCH included a total of 404 stage III NSCLC patients (202 patients in the combination of treprizumab and chemotherapy group and 202 patients in the combination of placebo and chemotherapy group), who were randomly treated with treprizumab or placebo combined with chemotherapy in a 1:1 ratio for 3 cycles before surgery and 1 cycle after surgery, Subsequently, they received 13 cycles of consolidation treatment with either Treprizumab or placebo (i.e., a "3+1+13" treatment mode). As of November 30, 2022 (median follow-up of 18.3 months), research results have shown that compared to chemotherapy alone, the combination of teriprizumab and chemotherapy during the perioperative period can significantly prolong the EFS of resectable stage III NSCLC patients with teriprizumab monotherapy consolidation treatment,